Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension

@article{OConnell2016ComparativeSA,
  title={Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension},
  author={Caroline O’Connell and D. Amar and A. Boucly and L. Savale and X. Jaı̈s and Marie-Camille Chaumais and D. Montani and M. Humbert and G. Simonneau and O. Sitbon},
  journal={Drug Safety},
  year={2016},
  volume={39},
  pages={287-294}
}
  • Caroline O’Connell, D. Amar, +7 authors O. Sitbon
  • Published 2016
  • Medicine
  • Drug Safety
  • Prostacyclin (PGI2) is a prostaglandin derived from arachidonic acid in the endothelium and smooth muscle which causes vasodilation, inhibits platelet aggregation, and has anti-inflammatory, anti-thrombotic and anti-proliferative effects. In pulmonary arterial hypertension (PAH), PGI2 levels and PGI2 synthase expression are reduced, contributing to the vasoconstriction and vascular smooth muscle cell proliferation seen in the disease. Based on these findings, PGI2 analogues were developed to… CONTINUE READING
    24 Citations
    Medical Treatment of Pulmonary Arterial Hypertension
    • 3
    Selexipag: A Review in Pulmonary Arterial Hypertension
    • 9
    Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.
    • 24
    • PDF

    References

    SHOWING 1-10 OF 56 REFERENCES
    Prostacyclin and its analogues in the treatment of pulmonary hypertension.
    • 115
    Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.
    • 744
    Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    • 229
    • PDF
    Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    • A. Yao
    • Medicine
    • Journal of cardiology
    • 2012
    • 21
    Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
    • 611
    • PDF
    Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.
    • 108
    Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
    • 1,254
    Beraprost therapy for pulmonary arterial hypertension.
    • 579
    • PDF